Protagenic Therapeutics Statistics
Want to see PTIX full AI Analyst Report?
Protagenic Therapeutics (PTIX) Stock Statistics & Valuation Metrics
Total Valuation
Protagenic Therapeutics has a market cap or net worth of $977.51K. The enterprise value is $1.69T.
- Market Cap
- $977.51K
- Enterprise Value
- $1.69T
Share Statistics
Protagenic Therapeutics has 1,810,208 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 1,810,208
- Owned by Insiders
- 4.06%
- Owned by Institutions
- 1.38%
Financial Efficiency
Protagenic Therapeutics’s return on equity (ROE) is 2.16 and return on invested capital (ROIC) is 379.69%.
- Return on Equity (ROE)
- 2.16
- Return on Assets (ROA)
- -2.42
- Return on Invested Capital (ROIC)
- 379.69%
- Return on Capital Employed (ROCE)
- 1.24
- Revenue Per Employee
- 0
- Profits Per Employee
- -2.58M
- Employee Count
- 2
- Asset Turnover
- 0.00
- Inventory Turnover
- 35.12
Valuation Ratios
The current PE Ratio of Protagenic Therapeutics is 0.18. Protagenic Therapeutics’s PEG ratio is 0.00.
- PE Ratio
- 0.18
- PS Ratio
- 0.00
- PB Ratio
- 0.88
- Price to FCF
- -0.62
- Price to Operating Cash Flow
- -0.62
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Protagenic Therapeutics had revenue of 0 and earned -5.16M in profits. Earnings per share was -3.45.
- Revenue
- 0
- Gross Profit
- -37.72K
- Operating Income
- -5.83M
- Pretax Income
- -5.16M
- Net Income
- -5.16M
- EBITDA
- -7.10M
- Earnings Per Share (EPS)
- -3.45
Cash Flow
In the last 12 months, operating cash flow was -1.58M and capital expenditures -3,299, giving a free cash flow of -1.58M billion.
- Operating Cash Flow
- -1.58M
- Free Cash Flow
- -1.58M
- Free Cash Flow per Share
- -0.87
Dividends & Yields
Protagenic Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -160.94%
- Earnings Yield
- 576.46%
Stock Price Statistics
- Beta
- -1.71
- 52-Week Price Change
- -73.66%
- 50-Day Moving Average
- 0.81
- 200-Day Moving Average
- 0.57
- Relative Strength Index (RSI)
- 27.40
- Average Volume (3m)
- 13.38K
Important Dates
Protagenic Therapeutics upcoming earnings date is ―, After Close (Confirmed).
- Last Earnings Date
- Apr 01, 2024
- Next Earnings Date
- ―
- Ex-Dividend Date
- ―
Financial Position
Protagenic Therapeutics as a current ratio of 0.34, with Debt / Equity ratio of -131.90%
- Current Ratio
- 0.34
- Quick Ratio
- 0.34
- Debt to Market Cap
- 1.25
- Net Debt to EBITDA
- -0.13
- Interest Coverage Ratio
- -19.64
Taxes
In the past 12 months, Protagenic Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Protagenic Therapeutics EV to EBITDA ratio is -0.24, with an EV/FCF ratio of -0.57.
- EV to Sales
- 0.00
- EV to EBITDA
- -0.24
- EV to Free Cash Flow
- -0.57
- EV to Operating Cash Flow
- -0.57
Balance Sheet
Protagenic Therapeutics has $76.91K in cash and marketable securities with $0.00 in debt, giving a net cash position of $76.91K billion.
- Cash & Marketable Securities
- $76.91K
- Total Debt
- $0.00
- Net Cash
- $76.91K
- Net Cash Per Share
- $0.04
- Tangible Book Value Per Share
- -$0.64
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Scores
- Smart Score
- ―
- AI Score
- 27
